Roger Perlmutter

Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma Med in Pivotal Testing

Eikon Therapeutics’ lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also developing PARP inhibitors that could have advantages over cancer drugs currently available from this class.

By Frank Vinluan

BioPharma

Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helm

Eikon Therapeutics joins a growing number of startups researching how proteins move in cells as a basis for drug discovery. Roger Perlmutter joins Eikon as its CEO just four months after he retired as Merck’s top research executive.

By Frank Vinluan